Pseudomonas aeruginosa pneumonia

Current Opinion in Infectious Diseases

Volumn 16, Issue 2, 2003, Pages 135-143

  Garau, Javier ^a,b   Gomez, Lucia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

Cystic fibrosis; P. aeruginosa pneumonia; P. aeruginosa VAP; Pseudomonas aeruginosa; Treatment P. aeruginosa infections; Treatment P. aeruginosa respiratory tract infections; VAP

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOPERAZONE; CEFSULODIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; ERYTHROMYCIN; IMIPENEM; JOSAMYCIN; MEROPENEM; MONOBACTAM DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SECRETORY PROTEIN; TOBRAMYCIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; BRONCHOSPASM; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG BIOAVAILABILITY; HOSPITAL INFECTION; HUMAN; LUNG FUNCTION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHENOTYPE; PREVALENCE; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW;

EID: 0037397798     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200304000-00010     Document Type: Review

References (42)

1. Giamarellou H. Therapeutic guidelines for Pseudomonas aeruginosa infections. Int J Antimicrob Agents 2000; 16:103-106.
2. Almirall J, Mesalles E, Klamburg J, et al. Prognostic factors of pneumonia requiring admission to the intensive care unit. Chest 1995; 107:511-516.
3. Dahmash NS, Chowdhury MN. Re-evaluation of pneumonia requiring admission to an intensive care unit: a prospective study. Thorax 1994; 49:71-76.
4. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to Gram-negative bacteria and Pseudomonas aeruginosa. Arch Int Med 2002; 162:1849-1858. Pseudomonas aeruginosa is an important pathogen in the subgroup of patients with severe CAP, pulmonary comorbidity and recent history of previous hospitalization.
5. Hatchette T, Gupta R, Marrie TJ. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis 2000; 31:1349-1356.
6. Trouillet JL, Vaugnat A, Combes A, et al. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002; 34:1047-1054. This paper highlights the major role that the fluoroquinolones play in the emergence of multiply resistant P. aeruginosa responsible for VAP.
7. Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am Rev Resp Dis 1989; 139:877-884.
8. Patel P, Whittier S, Frank E. Person-to-person transmission of Pseudomonas pneumonia in the community: documentation by pulsed-field electrophoresis. South Med J 2002; 95:653-656.
9. McCallum SJ, Gallagher MJ, Corkill JE, et al. Spread of an epidemic Pseudomonas aeruginosa strain from a patient with cystic fibrosis (CF) to non-CF relatives. Thorax 2002; 57:559-560.
10. Chastre J, Fagon J-Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903. An excellent in depth review of all relevant clinical aspects of ventilator-associated pneumonia.
11. Woske HJ, Roding T, Schulz I, Lode H. Ventilator-associated pneumonia in a surgical intensive care unit: epidemiolgy, etiology and comparison of three bronchscopic methods for microbiological specimen sampling. Crit Care 2001; 5:167-173.
12. Prats E, Dorca J, Pujol M, et al. Effects of antibiotics on protected specimen brush sampling in ventilator-associated pneumonia. Eur Resp J 2002; 19:944-951. This article shows the effect of antibiotic therapy in PSB samples in patients with VAP. Certain microorganisms are more susceptible than others and antibiotics can have a marked effect even after only 12 h of antibiotic administration. P, aeruginosa are more difficult to eradicate and can still be cultivated from samples even after 48 h of adequate antibiotic treatment.
13. Schultz MJ, Rijneveld AW, Florquin S, et al. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 2002; 282:L285-290.
14. Nieuwenhuis EE, Matsumoto T, Exley M, et al. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 2002; 8:588-593.
15. Roy-Burman A, Savel RH, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183:1767-1774. The authors analysed the prevalence and pathogenicity of type III secretory proteins in P. aeruginosa isolates from patients infected with this microorganism. This phenotype is associated with increased morbidity and mortality in animals and humans.
16. Hauser AR, Cobb E, Bodi M, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care 2002; 30:521-528. This paper confirms that type III secretory protein is a major virulent system of P. aeruginosa and is associated with worse outcomes in patients with P. aeruginosa VAP with this phenotype.
17. Gorman SP, McGovern JG, Woolfson AD, Adair CG, Jones DS. The concomitant development of poly (vinyl chloride) - related biofilm and antimicrobial resistance in relation to ventilation-associated pneumonia. Biomaterials 2001; 22:2741-2747.
18. Kaneko Y, Yanagihara K, Kuroki M, et al. Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia. Chemotherapy 2001; 47:421-429.
19. Yanagihara K, Tomono K, Imamura Y, et al. Effect of clarithrmycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. J Antimicrob Chemother 2002; 49:867-870.
20. Livermore D, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000; 3:489-495.
21. Bellais S, Mimoz O, Leotard S, et al. Efficacy of β-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-β-lactamase-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46:2032-2034. The authors studied the efficacy of β-lactams in a rat pneumonia model with a P. aeruginosa strain that produced the plasmid encoded MLB VIM-2, which exhibited high MICs to imipenem and other β-lactams and remained sensitive to aztreonam. There was a good response to treatment with high dose regimens with imipenem and other β-lactams and, interestingly enough, to aztreonam only with a high dosage. A low level expression of the MLB or a low catalytic efficacy may explain the paradoxical efficacy of these β-lactams.
22. Jean D, Maitre B, Tankovic J, et al. Beneficial effects of nitric oxide inhalation on pulmonary bacterial clearance. Crit Care Med 2002; 30:442-447.
23. Satoh S, Oishi K, Iwagaki A, et al. Dexamethasone impairs pulmonary defence against Pseudomonas aeruginosa through suppressing iNOS gene expression and peroxynitrite production in mice. Clin Exp Immunol 2001; 126:266-273.
24. Debon R, Breilh D, Boselli E, et al. Pharmacokinetic parameters of ciprofloxacin (500 mg/5 ml) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages. J Chemother 2002; 14:175-180.
25. Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA, Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrobial Agents 2002; 19:105-110.
26. Mattoes HM, Capitano B, Kim MK, et al. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375 g q4h and 4.5 g q6h. Chemotherapy 2002; 48:59-63.
27. Ambrose PG, Owens RC, Garvey MJ, Jones RN. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002; 49:445-453.
28. Dennesen PJ, van der Ven AJ, Kessels AG, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Resp Crit Care Med 2001; 163:1371-1375.
29. Fitzsimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122:1-9.
30. Whitehead A, Conway SP, Etherington C, et al. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 2002; 19:303-309.
31. Munck A, Bonacorsi S, Mariani-Kurkdjian P, et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001; 32:288-292.
32. Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122:219-226.
33. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis. Lancet 1991; 338:725-726.
34. Heinzl B, Eber E, Oberwaldner B, et al. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2002; 33:32-37.
35. West SE, Zeng L, Leng Lee B, et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis. Early detection by serology and assessment of risk factors. JAMA 2002; 287:2958-2967.
36. Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20:658-664.
37. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121:55-63. This article describes the effects of inhaled tobramycin given for two years to a group of adolescents with CF. At the end of the study, tobramycin-treated patients maintained an increase in FEV1 above baseline and the placebo group only maintained an increase of 1.8%. Also, they found a highly significant inverse correlation between the change in pulmonary function and the change in P. aeruginosa cfu density.
38. Nikolaizik WH, Trociewicz K, Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 2001; 20:122-126.
39. Alothman GA, Alsaadi MM, Ho BL, et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 2002; 122:930-934.
40. Sajjan US, Tran LT, Sole N, et al. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob Agents Chemother 2001; 45:3437-3444.
41. Saiman L, Tabibi S, Starner TD, et al. Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45:2838-2844.
42. Yanagihara K, Tomono K, Imamura Y, et al. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. J Antimicrob Chemother 2002; 49:867-870.